Baptist Health Medical Center, Jacksonville, Florida, USA.
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
J Clin Microbiol. 2024 Nov 13;62(11):e0094124. doi: 10.1128/jcm.00941-24. Epub 2024 Oct 21.
Diagnostic stewardship (DxS) for infectious disease testing requires a multi-disciplinary approach to optimize test selection, performance, interpretation and patient treatment. Nucleic acid amplification-based tests for the diagnosis of infectious diseases, or "molecular microbiology tests," have rapidly expanded over the past two decades. With the increased availability and complexity of these tests, there is also an increased need for collaborative approaches to optimize test use to promote positive impacts on patient care, while mitigating potential negative impact or resource waste. In this review, we provide recommendations on building collaborative DxS teams, including microbiologists and the diverse stakeholders that use and interpret molecular microbiology tests. We then detail approaches to identify high-priority molecular microbiology tests that may need utilization assessment, select appropriate diagnostic stewardship interventions, and monitor the impact of implemented interventions. This strategic process may be employed by laboratories to realize optimal testing for selected tests at their institution.
诊断管理(DxS)需要多学科方法来优化测试选择、性能、解释和患者治疗。基于核酸扩增的传染病诊断测试,或“分子微生物学测试”,在过去二十年中迅速扩展。随着这些测试的可用性和复杂性的增加,也需要协作方法来优化测试使用,以促进对患者护理的积极影响,同时减轻潜在的负面影响或资源浪费。在这篇综述中,我们提供了关于建立协作 DxS 团队的建议,包括微生物学家和使用和解释分子微生物学测试的各种利益相关者。然后,我们详细介绍了确定可能需要进行利用评估的高优先级分子微生物学测试、选择适当的诊断管理干预措施以及监测实施干预措施的影响的方法。该策略性流程可由实验室用于实现其机构中选定测试的最佳测试。